Tri Locum Partners LP Grows Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Tri Locum Partners LP raised its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 102.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 227,762 shares of the biotechnology company’s stock after purchasing an additional 115,092 shares during the quarter. Ascendis Pharma A/S makes up about 7.9% of Tri Locum Partners LP’s portfolio, making the stock its 3rd biggest holding. Tri Locum Partners LP owned 0.39% of Ascendis Pharma A/S worth $31,062,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Profund Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock valued at $398,000 after buying an additional 85 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Ascendis Pharma A/S by 37.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 91 shares in the last quarter. GAMMA Investing LLC lifted its stake in Ascendis Pharma A/S by 52.0% in the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 102 shares during the last quarter. Rhumbline Advisers grew its position in shares of Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares during the period. Finally, Quadrant Capital Group LLC grew its position in shares of Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 151 shares during the period.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Citigroup raised their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Evercore ISI raised their price objective on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. Wells Fargo & Company boosted their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. Oppenheimer restated an “outperform” rating and issued a $190.00 price target (up previously from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, September 17th. Finally, The Goldman Sachs Group lifted their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $193.77.

Ascendis Pharma A/S Stock Down 1.4 %

Shares of NASDAQ:ASND opened at $151.26 on Monday. Ascendis Pharma A/S has a 12-month low of $85.29 and a 12-month high of $161.00. The company’s 50 day moving average price is $133.56 and its two-hundred day moving average price is $136.50. The firm has a market cap of $8.81 billion, a PE ratio of -15.74 and a beta of 0.63.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.